Canaccord Genuity Group Forecasts Strong Price Appreciation for Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare (NYSE:PBH) had its price target lifted by Canaccord Genuity Group from $93.00 to $100.00 in a report published on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other research analysts have also issued research reports about the stock. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, DA Davidson upped their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $92.50.

Prestige Consumer Healthcare Price Performance

PBH opened at $86.96 on Friday. The company has a fifty day simple moving average of $79.19 and a 200 day simple moving average of $75.34. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.30 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50. Prestige Consumer Healthcare has a 12 month low of $60.00 and a 12 month high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last three months. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $27,000. Northwestern Mutual Wealth Management Co. increased its position in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares during the last quarter. nVerses Capital LLC raised its stake in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the period. Huntington National Bank lifted its position in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after acquiring an additional 1,138 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.